High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virus–Coinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands

Boerekamps, Anne; Newsum, Astrid M.; Smit, Colette; Arends, Joop E.; Richter, Clemens; Reiss, Peter; Rijnders, Bart J. A.; Brinkman, Kees; Valk, Marc van der

doi:10.1093/cid/cix1004

Cited by 60 publications

(50 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Includes those who have tested HCV RNA positive, were treated with DAAs, have never been treated, or were treated with interferon‐based therapies and failed treatment but have not yet been retreated . …”

Section: Results ‐ Progress Toward Hcv Elimination In Hiv‐infected Pomentioning

confidence: 99%

“…HCV diagnosis rates among HIV-infected populations are not currently well understood and additional research is required to estimate [42]. c Cascade of care from the ATHENA cohort of people diagnosed with HIV in the Netherlands from a period where DAAs were broadly available but prior to MC Free, Amsterdam [45]. A cascade of care at the two largest HIV clinics in Amsterdam (a subset of the ATHENA cohort) is available for the same period [46].…”

Section: Discussionmentioning

confidence: 99%

“…f As of 21 November 2013 (Health Canada's approval of second-generation DAAs), cohort participants who were eligible to initiate DAAs. g Includes those who have tested HCV RNA positive, were treated with DAAs, have never been treated, or were treated with interferon-based therapies and failed treatment but have not yet been retreated [45]. h Of those HCV RNA positive.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era

et al. 2018

Self Cite

View full text Add to dashboard Cite

IntroductionThere is currently no published data on the effectiveness of DAA treatment for elimination of HCV infection in HIV‐infected populations at a population level. However, a number of relevant studies and initiatives are emerging. This research aims to report cascade of care data for emerging HCV elimination initiatives and studies that are currently being evaluated in HIV/HCV co‐infected populations in the context of implementation science theory.Methods HCV elimination initiatives and studies in HIV co‐infected populations that are currently underway were identified. Context, intervention characteristics and cascade of care data were synthesized in the context of implementation science frameworks.ResultsSeven HCV elimination initiatives and studies were identified in HIV co‐infected populations, mainly operating in high‐income countries. Four were focused mainly on HCV elimination in HIV‐infected gay and bisexual men (GBM), and three included a combination of people who inject drugs (PWID), GBM and other HIV‐infected populations. None were evaluating treatment delivery in incarcerated populations. Overall, HCV RNA was detected in 4894 HIV‐infected participants (range within studies: 297 to 994): 48% of these initiated HCV treatment (range: 21% to 85%; within studies from a period where DAAs were broadly available the total is 57%, range: 36% to 74%). Among studies with treatment completion data, 96% of 1109 initiating treatment completed treatment (range: 94% to 99%). Among those who could be assessed for sustained virological response at 12 weeks (SVR12), 1631 of 1757 attained SVR12 (93%, range: 86% to 98%).ConclusionsEarly results from emerging research on HCV elimination in HIV‐infected populations suggest that HCV treatment uptake is higher than reported levels prior to DAA treatment availability, but approximately half of patients remain untreated. These results are among diagnosed populations and additional effort is required to increase diagnosis rates. Among those who have initiated treatment, completion and SVR rates are promising. More data are required in order to evaluate the effectiveness of these elimination programmes in the long term, assess which intervention components are effective, and whether they need to be tailored to particular population groups.

show abstract

Section: Results ‐ Progress Toward Hcv Elimination In Hiv‐infected Pomentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…In the 2 treatment failures, the baseline HCV viral loads were 9.8E5 and 8.7E6 IU/ml. The subtype was 4c in one patient, but in the other As a result of the rapid treatment uptake of DAAs in HIVinfected MSM in the Netherlands and Belgium, 11 the inclusion of additional patients was not possible because after the screening of 63 and the treatment of 40 genotype 4 patients, no eligible patients were left in any of the participating centers. Therefore, we did not reach the intended sample size of 41 patients as stated in the protocol of our study (as described supplementary information).…”

mentioning

confidence: 99%

8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

Boerekamps

Vanwolleghem

Valk

et al. 2019

Journal of Hepatology

Self Cite

View full text Add to dashboard Cite

Wouthuyzen-Bakker: treating physician, critical revision of the manuscript. Robert J de Knegt: treating physician, critical revision of the manuscript. Pieter Honkoop: treating physician, critical revision of the manuscript. Omar El-Sherif: supervision of sample analysis, critical revision of the manuscript. Angela Colbers: analysis of data, critical revision of the manuscript. David J Back: critical revision of the manuscript. David M Burger: interpretation of results, critical revision of the manuscript, supervision of the case series.

show abstract

“…In addition, treating chronic HCV infections with direct acting antivirals (DAAs) is expected to strongly reduce, but not eliminate, the HCV epidemic among HIV-positive MSM [5,6]. Despite high DAA uptake in HIV/HCV co-infected people in the Netherlands [7], ongoing HCV transmission and reinfection continue to occur.…”

Section: Introductionmentioning

confidence: 99%

Acute hepatitis C infection among adults with HIV in the Netherlands: a capture-recapture analysis

Boender

Arends

et al. 2019

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Reliable surveillance systems are essential to assess the national response to eliminating hepatitis C virus (HCV), in the context of the global strategy towards eliminating viral hepatitis. Aim: We aimed to assess the completeness of the two national registries of acute HCV infection in people with HIV, and estimated the number of acute HCV infections among adults with HIV in the Netherlands. Methods: For 2003-2016, cases of HCV infection and reinfection among adults with a positive or unknown HIV-serostatus were identified in two national registries: the ATHENA cohort, and the National Registry for Notifiable Diseases. For 2013-2016, cases were linked, and two-way capture-recapture analysis was carried out. Results: During 2013-2016, there were an estimated 282 (95%CI: 264-301) acute HCV infections among adults with HIV. The addition of cases with an unknown HIV-serostatus increased the matches (from N=104 to N=129), and a subsequently increased the estimated total: 330 (95%CI: 309-351). Underreporting was estimated at 14-20%. Conclusion: In 2013-2016, up to 330 cases of acute HCV infection were estimated to have occurred among adults with HIV. National surveillance of acute HCV can be improved by increased notification of infections. Surveillance data should ideally include both acute and chronic HCV infections, and be able to distinguish between acute and chronic infections, and initial and reinfections.

show abstract

High Treatment Uptake in Human Immunodeficiency Virus/Hepatitis C Virus–Coinfected Patients After Unrestricted Access to Direct-Acting Antivirals in the Netherlands

Abstract: Fifteen months after unrestricted DAA availability the majority of HIV/HCV-coinfected patients in the Netherlands have their HCV infection cured (76%) or are awaiting DAA treatment results (6%). This rapid treatment scale-up may contribute to future HCV elimination among these patients.

Cited by 60 publications

References 13 publications

Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era

Linkage and retention in HCV care for HIV‐infected populations: early data from the DAA era

8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)

Acute hepatitis C infection among adults with HIV in the Netherlands: a capture-recapture analysis

Contact Info

Product

Resources

About